| Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee |
110 |
| Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR) |
19 |
| Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations* |
16 |
| Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use? |
13 |
| Reduced left atrial myocardial deformation irrespective of cavity size: a potential cause for atrial arrhythmia in hereditary transthyretin amyloidosis |
12 |
| Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study(#) |
12 |
| Polymorph-specific distribution of binding sites determines thioflavin-T fluorescence intensity in -synuclein fibrils |
11 |
| Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality |
11 |
| Diflunisal tolerability in transthyretin cardiac amyloidosis: a single center's experience |
10 |
| Seven factors predict a delayed diagnosis of cardiac amyloidosis |
9 |
| Sudoscan in the evaluation and follow-up of patients and carriers with TTR mutations: experience from an Italian Centre |
8 |
| Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis |
8 |
| Regional amyloid distribution and impact on mortality in light-chain amyloidosis: a T1 mapping cardiac magnetic resonance study |
8 |
| First nationwide survey on systemic wild-type ATTR amyloidosis in Japan |
6 |
| A pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement |
6 |
| Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients |
6 |
| MRI feature tracking strain is prognostic for all-cause mortality in AL amyloidosis |
6 |
| Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial |
6 |
| Right ventricular involvement in transthyretin amyloidosis |
5 |
| Quantitation of Tc-99m-DPD uptake in patients with transthyretin-related cardiac amyloidosis |
5 |
| Profile of renal AA amyloidosis in older and younger individuals: a single-centre experience |
5 |
| Obesity is a significant susceptibility factor for idiopathic AA amyloidosis |
5 |
| Right ventricular longitudinal strain: a tool for diagnosis and prognosis in light-chain amyloidosis |
5 |
| A new era of amyloidosis: the trends at a major US referral centre |
4 |
| Transthyretin deposition in the eye in the era of effective therapy for hereditary ATTRV30M amyloidosis |
4 |
| Assessment of patients with hereditary transthyretin amyloidosis - understanding the impact of management and disease progression |
4 |
| Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome |
4 |
| Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis |
4 |
| Peak V'O-2 is an independent predictor of survival in patients with cardiac amyloidosis |
3 |
| A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy |
3 |
| Validation of the Boston University staging system in AL amyloidosis |
3 |
| AmyCo: the amyloidoses collection |
3 |
| Founder effect of the Glu89Gln TTR mutation in the Bulgarian population |
3 |
| Lipid membranes accelerate amyloid formation in the mouse model of AA amyloidosis |
3 |
| Cause of death analysis and temporal trends in survival after liver transplantation for transthyretin familial amyloid polyneuropathy |
3 |
| Gastrointestinal perforation in light chain amyloidosis in the era of novel agent therapy - a case series and review of the literature |
2 |
| Psychopathological dimensions in subjects with hereditary ATTR V30M amyloidosis and their relation with life events due to the disease |
2 |
| Amyloid in parenchymal organs in gelsolin (AGel) amyloidosis |
2 |
| Idiopathic degenerative thoracic aneurysms are associated with increased aortic medial amyloid |
2 |
| Prevalence of TTR variants detected by whole-exome sequencing in hypertrophic cardiomyopathy |
2 |
| Prevalence of cardiac amyloidosis among elderly patients with systolic heart failure or conduction disorders |
2 |
| A functional assay to identify amyloidogenic light chains |
2 |
| Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study |
2 |
| A library of ATTR amyloidosis patient-specific induced pluripotent stem cells for disease modelling and in vitro testing of novel therapeutics |
2 |
| Morphological and primary structural consistency of fibrils from different AA patients (common variant) |
2 |
| Association between hearing loss and hereditary ATTR amyloidosis |
2 |
| Epidemiology of Castleman disease associated with AA amyloidosis: description of 2 new cases and literature review |
2 |
| Sjogren syndrome-related plasma cell disorder and multifocal nodular AL amyloidosis: clinical picture and pathological findings |
1 |
| Electrophysiological demyelinating features in hereditary ATTR amyloidosis |
1 |
| Cell assay for the identification of amyloid inhibitors in systemic AA amyloidosis |
1 |
